# Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

> **NCT06498973** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 43 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Tagraxofusp-erzs

## Key facts

- **NCT ID:** NCT06498973
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-28
- **Primary completion:** 2027-04-25
- **Final completion:** 2027-04-25
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498973, "Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06498973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*